UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chiari I malformation in the very young child: the spectrum of presentations and experience in 31 children under age 6 years

Pediatrics (Evanston), 2002-12, Vol.110 (6), p.1212-1219

2002

Volltextzugriff (PDF)

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker

Blood, 2003-04, Vol.101 (7), p.2557-2562

2003

Volltextzugriff (PDF)

Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma

American journal of hematology, 2016-06, Vol.91 (6), p.571-574

2016

Volltextzugriff (PDF)

Primary bone tumors of the spine in children

Journal of neurosurgery, 2006-10, Vol.105 (4 Suppl), p.252-260

2006

Volltextzugriff (PDF)

Calcium pyrophosphate dihydrate crystal deposition in the craniovertebral junction

Journal of neurosurgery. Spine, 2008-01, Vol.8 (1), p.22-29

2008

Volltextzugriff (PDF)

IL-1-6 Blocking IL-1 beta to prevent progression to multiple myeloma

Cytokine (Philadelphia, Pa.), 2010-10, Vol.52 (1-2), p.10-10

2010

Volltextzugriff (PDF)

Eosinophilic Granuloma in the Pediatric Spine

Pediatric neurosurgery, 2007-01, Vol.43 (4), p.285-292

2007

Volltextzugriff (PDF)

Syringobulbia in a Pediatric Population

Neurosurgery, 2005-12, Vol.57 (6), p.1147-1153

2005

Volltextzugriff (PDF)

Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1

Journal of interferon & cytokine research, 2006-02, Vol.26 (2), p.83-95

2006

Volltextzugriff (PDF)

Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor

Cytokine (Philadelphia, Pa.), 1992-03, Vol.4 (2), p.96-100

1992

Volltextzugriff (PDF)

Honored guest presentation: lifetime experiences and where we are going: Chiari I with syringohydromyelia--controversies and development of decision trees

Clinical neurosurgery, 2005, Vol.52, p.297

2005

Volltextzugriff (PDF)

Interplay Between IL-1, IL-6 and IL-17 in IL-1 Receptor Antagonist (IL-1Ra) Treated Multiple Myeloma Patients

Blood, 2012-11, Vol.120 (21), p.1874-1874

2012

Volltextzugriff (PDF)

Honored guest presentation: surgery at the crossroads: craniocervical neoplasms

Clinical neurosurgery, 2005, Vol.52, p.218

2005

Volltextzugriff (PDF)

Abstract 2582: P2X7 receptor is functional in myeloma cell lines and myeloma patient cells and can be modulated by P2X7 receptor antagonists: Implications for myeloma therapy

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2582-2582

2011

Volltextzugriff (PDF)

Functional P2X7 Receptors in Myeloma Cell Lines and Myeloma Patient Bone Marrow Samples Can Be Blocked by Specific P2X7 Receptor Antagonists: Implications for Myeloma Therapy and Chemotherapy Induced Inflammation

Blood, 2011-11, Vol.118 (21), p.1845-1845

2011

Volltextzugriff (PDF)

IL-1 Antagonists Are More Effective at Inhibiting IL-6 Production Than Apoptosis Inducing Agents: Implications for Targeting the Myeloma Proliferative Component

Blood, 2009-11, Vol.114 (22), p.1831-1831

2009

Volltextzugriff (PDF)

ITF2357, a Novel Histone Deacetylase Inhibitor, Demonstrates Significant Apoptotic Activity Against Human Multiple Myeloma Cells

Blood, 2007-11, Vol.110 (11), p.4791-4791

2007

Volltextzugriff (PDF)

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

Blood, 2011-11, Vol.118 (21), p.2945-2945

2011

Volltextzugriff (PDF)

Systemic Delivery of the Cancer Gene Therapy Biologic, SNS01, Has Significant Anti-Tumoral Activity in a Murine Model of Multiple Myeloma

Blood, 2009-11, Vol.114 (22), p.2462-2462

2009

Volltextzugriff (PDF)

THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA

Hematology/oncology clinics of North America, 1999-12, Vol.13 (6), p.1117-1125

1999

Volltextzugriff (PDF)

Preclinical Studies Using Polyethylenimine (PEI) Nanoparticles Complexed with Eukaryotic Translation Initiation Factor 5A (eIF5A) siRNA and eIF5AK50R Plasmid DNA Demonstrates Significant Anti-Myeloma Activity in Vitro and in Vivo

Blood, 2008-11, Vol.112 (11), p.249-249

2008

Volltextzugriff (PDF)

Comparison of Interleukin-1β Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

Blood, 1999-01, Vol.93 (1), p.300-305

1999

Volltextzugriff (PDF)

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

Mayo Clinic proceedings, 2009-02, Vol.84 (2), p.114

2009

Volltextzugriff (PDF)

1 – 25 von 279

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(205)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(278)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(137)
Life Sciences & Biomedicine
(128)
Humans
(116)
Male
(75)
Female
(71)
Biological And Medical Sciences
(47)
Medical Sciences
(39)
Adult
(33)
Middle Aged
(33)
Aged
(24)
Adolescent
(23)
Pediatrics
(18)
Treatment Outcome
(17)
General & Internal Medicine
(16)
Public, Environmental & Occupational Health
(16)
Risk Factors
(16)
Animals
(15)
Young Adult
(15)
Child
(14)
Clinical Trials
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component

Chiari I malformation in the very young child: the spectrum of presentations and experience in 31 children under age 6 years

Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker

Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma

Primary bone tumors of the spine in children

Calcium pyrophosphate dihydrate crystal deposition in the craniovertebral junction

IL-1-6 Blocking IL-1 beta to prevent progression to multiple myeloma

Eosinophilic Granuloma in the Pediatric Spine

Syringobulbia in a Pediatric Population

Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1

Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor

Honored guest presentation: lifetime experiences and where we are going: Chiari I with syringohydromyelia--controversies and development of decision trees

Interplay Between IL-1, IL-6 and IL-17 in IL-1 Receptor Antagonist (IL-1Ra) Treated Multiple Myeloma Patients

Honored guest presentation: surgery at the crossroads: craniocervical neoplasms

Abstract 2582: P2X7 receptor is functional in myeloma cell lines and myeloma patient cells and can be modulated by P2X7 receptor antagonists: Implications for myeloma therapy

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

Functional P2X7 Receptors in Myeloma Cell Lines and Myeloma Patient Bone Marrow Samples Can Be Blocked by Specific P2X7 Receptor Antagonists: Implications for Myeloma Therapy and Chemotherapy Induced Inflammation

IL-1 Antagonists Are More Effective at Inhibiting IL-6 Production Than Apoptosis Inducing Agents: Implications for Targeting the Myeloma Proliferative Component

ITF2357, a Novel Histone Deacetylase Inhibitor, Demonstrates Significant Apoptotic Activity Against Human Multiple Myeloma Cells

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

Systemic Delivery of the Cancer Gene Therapy Biologic, SNS01, Has Significant Anti-Tumoral Activity in a Murine Model of Multiple Myeloma

THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA

Preclinical Studies Using Polyethylenimine (PEI) Nanoparticles Complexed with Eukaryotic Translation Initiation Factor 5A (eIF5A) siRNA and eIF5AK50R Plasmid DNA Demonstrates Significant Anti-Myeloma Activity in Vitro and in Vivo

Comparison of Interleukin-1β Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

Suchergebnisse filtern